Biosimilars and Biologics. Implementation and Monitoring in a Healthcare Setting

Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics.

This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including:

• Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines
• The safety, efficacy, and interchangeability of biologics
• The science and analytical chemistry associated with the manufacture of biologics
• Needed pharmacovigilance and adverse effect reporting systems
• Formulary management